Precigen UltraCAR-T Technology Flexes its Muscles at ASH Meeting

Published on :

At the American Society of Hematology meeting earlier this month, Precigen presented positive interim data from an ongoing Phase 1/2b clinical study of PRGN-3006 UltraCAR-T in patients who have been diagnosed with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). The interim study data showed what the trial investigators are calling “excellent, dose-dependent expansion.”